Nephropathy Clinical Trials

A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd)

The research study is being conducted to see how well the investigational drug, Nefecon, works for the treatment of your kidney disease and more specific for patients with "primary immunoglobulin A nephropathy," called IgAN.

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS-IgAN)

This study will use a new investigational study drug called OMS721 in people with Immunoglobulin A (IgA) Nephropathy. This kidney disease produces abnormal amounts of a protein called IgA in the kidney that damage the filtering units or glomeruli.

The Nephrotic Syndrome Study Network

We are particularly interested in the diseases called Focal and Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), and Membranous Nephropathy (MN), which are three common causes of Nephrotic Syndrome.

None

None

None

None

Kidney Disorders: Biological Specimen Repository and Clinical Database

To support the research of kidney disorders by creating a bank of biospecimens and a corresponding database of clinical information that will be used for future, unspecified research.

MRI Quantification of Hip Bone Microstructure in Stage 4 and 5 Chronic Kidney Disease

University of Pennsylvania Department of Radiology is conducting a research study on hip bone microstructure and strength in people with AND without chronic renal disease. The purpose of this research is to examine the microstructure of bone in the hip using a new, MRI-based approach.